Other pharmacological classes assessed for their ability to blunt opioid-induced respiratory depression include PKA inhibitors, GIRK inhibitors, and thyrotropin-releasing hormone (TRH) analogs. Here, TRH is linked to Respiratory insufficiency due to muscle weakness.